SCHEMBL23591985

SCHEMBL23591985

C=CC(=O)Nc1cccnc1C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.51
PTPN11 Q06124 1/20 0.51
TGM2 P21980 4/20 0.46
F13A1 P00488 1/20 0.44
TGM1 P22735 1/20 0.44
TGM3 Q08188 1/20 0.44
EGFR P00533 1/20 0.43
FGFR1 P11362 1/20 0.43
FGFR4 P22455 1/20 0.43
MAPK3 P27361 1/20 0.43
MAPK1 P28482 1/20 0.43
MAP2K1 Q02750 1/20 0.43
RORC P51449 2/20 0.43
P2RX7 Q99572 1/20 0.42
KDM4E B2RXH2 2/20 0.42
RECQL P46063 1/20 0.42
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
BTK Q06187 2/20 0.41
JAK3 P52333 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2866574 0.81 PTPN1 (0.53) PTPN1PTPN11TGM2F13A1TGM1
SCHEMBL965253 0.80 P2RX7 (0.49) P2RX7KDM4ENPC1RAB9AMEN1
SCHEMBL269101 0.79 MEN1 (0.60) MAPK1P2RX7MEN1KMT2A
SCHEMBL30511903 0.78 KDM4E (0.69) KDM4ERECQLNPC1RAB9AMEN1
SCHEMBL11262478 0.78 KDM4E (0.69) KDM4ERECQLNPC1RAB9AMEN1
SCHEMBL18525486 0.77 RAB9A (0.57) TGM2F13A1TGM1TGM3MAPK1
SCHEMBL2544479 0.76 PTPN1 (0.81) PTPN1PTPN11KDM4ERECQLMEN1
SCHEMBL22103681 0.76 POLB (0.64) P2RX7KDM4ERECQLNPC1RAB9A
SCHEMBL613090 0.76 TGM2 (0.65) PTPN1PTPN11TGM2F13A1TGM1
SCHEMBL31228347 0.76 TGM2 (0.65) PTPN1PTPN11TGM2F13A1TGM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192607-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-06-22 US disclosed
US-20230192607-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-06-22 US disclosed
WO-2021133896-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2021-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192607-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF TEAD1, TEAD4, TEAD2 PTPN1 4042/4885PTPN11 3669/4885TGM2 765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.